Drug Trial Radar · NCT04038502
Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Oct 1, 2019
Primary completion
Aug 31, 2027
Study completion Aug 31, 2027
Sponsor
- Lead sponsor
- VA Office of Research and DevelopmentFederal agency
- Sponsor type
- Federal agency
- First posted
- Jul 30, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Health services research
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an unblinded, randomized clinical study comparing the efficacy of DNA damaging chemotherapy using carboplatin, to standard of care therapy for patients who have metastatic castrate resistant prostate cancer. This trial will use olaparib or carboplatin as initial therapy with crossover to the alternate or second-line drug after first progression for patients with tumors containing BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D, or RAD54L inactivating mutations. Participants are randomized (1:1) and receive either carboplatin (AUC 5, IV) every 21 days, first or olaparib taken orally (300 mg), twice daily in 28 day cycles, until intolerance, complete response, or progression by Prostate Cancer Working Group 3 (PCWG3) criteria. Participants then crossover from the first-line therapy to the second-line therapy with the opposite study medication and receive treatment to intolerance or progression (whichever is first). Enrolled participants will be allowed to crossover to second line therapy if they continue to meet initial eligibility criteria, and at least three weeks have elapsed since last administration of either carboplatin or olaparib. Throughout the study, safety and tolerability will be assessed. Progression will be evaluated with bone scan, CT of the abdomen/pelvis, or MRI and PSA as per PCWG3 criteria.
Conditions
- Metastatic Castrate Resistant Prostate Cancer
- BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2
- RAD51B, RAD51C, RAD51D, or RAD54L Mutations
Interventions
CarboplatinDrug
Chemotherapy FDA approved drug used to treat: ovarian, lung, head and neck cancers. It is sometimes used in combination with other medications or off-label use to treat other metastatic cancers.
OlaparibDrug
Olaparib is a targeted therapy drug that is used for mCRPC and is approved by the FDA for this use.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS-1L) defined as the time interval between randomization and first documented disease progression or death due to any cause reported during, or after, first-line treatmentTime frame: Through duration of the study, up to 100 weeks
Locations
18 sites in 1 country. Site status is shown where the registry gives one.
VA Greater Los Angeles Healthcare System, West Los Angeles, CA
West Los Angeles, California · Recruiting
Rocky Mountain Regional VA Medical Center, Aurora, CO
Aurora, Colorado · Recruiting
Washington DC VA Medical Center, Washington, DC
Washington D.C., District of Columbia · Recruiting
Bay Pines VA Healthcare System, Pay Pines, FL
Bay Pines, Florida · Terminated
Orlando VA Medical Center, Orlando, FL
Orlando, Florida · Recruiting
Atlanta VA Medical and Rehab Center, Decatur, GA
Decatur, Georgia · Recruiting
Boise VA Medical Center, Boise, ID
Boise, Idaho · Recruiting
Jesse Brown VA Medical Center, Chicago, IL
Chicago, Illinois · Terminated
VA Ann Arbor Healthcare System, Ann Arbor, MI
Ann Arbor, Michigan · Recruiting
Minneapolis VA Health Care System, Minneapolis, MN
Minneapolis, Minnesota · Recruiting
Kansas City VA Medical Center, Kansas City, MO
Kansas City, Missouri · Recruiting
Manhattan Campus of the VA NY Harbor Healthcare System, New York, NY
New York, New York · Recruiting
James J. Peters VA Medical Center, Bronx, NY
The Bronx, New York · Terminated
Durham VA Medical Center, Durham, NC
Durham, North Carolina · Recruiting
VA Portland Health Care System, Portland, OR
Portland, Oregon · Recruiting
Philadelphia MultiService Center, Philadelphia, PA
Philadelphia, Pennsylvania · Recruiting
VA Puget Sound Health Care System Seattle Division, Seattle, WA
Seattle, Washington · Recruiting
William S. Middleton Memorial Veterans Hospital, Madison, WI
Madison, Wisconsin · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.